Antibody therapy for critical Covid patients is recommended by the WHO.

The WHO Guideline Development Group (GDG) committee recommends combination casirivimab and imdevimab. The panel found that any benefits of this anti-body therapy are unlikely to be beneficial to all other Covid-19 patients.

According to the most recent World Health Organization recommendations published in The BMJ on Friday, condo-19 patients at a high risk of hospitalization or those with severe illness should be given a combination of two antibody therapies.For two distinct groups of patients with Covid-19, the WHO Guideline Development Group (GDG) committee recommends combination casirivimab and imdevimab.The first group is composed of patients with non-severe Covid-19 who are at risk of hospitalization, and the second group is composed of patients with severe or severe Covid-19 who are seronegative, meaning they have not mounted their own antibody response to Covid-19.The first recommendation is based on recent findings from three experiments that have yet to be peer reviewed.

The second suggestion is based on findings from a recent study, which indicates that the two antibodies could minimize deaths and the need for mechanical ventilation in seronegative patients.According to this study, treatment with Casirivimab and imdevimab resulted in 49 fewer deaths per 1,000 patients who were seriously ill and 87 fewer deaths in the critically ill.The panel found that any benefits of this anti-body therapy are unlikely to be beneficial to all other Covid-19 patients.Casirivimab and imdevimab are two monoclonal antibodies that conjugate with the SARS-CoV-2 spike protein, neutralizing the virus's ability to infect cells.

The panel discussed the risks associated with this approach, which may make finding out about low and middle-income countries difficult.Rapid serological examinations will be required to identify deemed sick patients, medical services will be delivered intravenously using advanced equipment, and patients will be monitored for allergic reactions.They also acknowledge the danger that new variants of casirivimab and imdevimab antibodies may have a less harmful effect.However, the committee says that given the demonstrated benefits for patients, the recommendations should serve as a reminder to use all possible mechanisms to expand global access to the intervention and its testing.

Regardless of disease severity, the committee advises against the use of ivermectin and hydroxychloroquine in Covid-19 patients.